Pharmacokinetics and bioavailability of doxycycline in turkeys. 1996

M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Gent, Belgium.

The pharmacokinetic parameters of doxycycline (DOX) were determined in 3 day, 3-, 6- and 12-week-old fasted turkeys, after a single intravenous (i.v.) dose of 25 mg doxycycline. HCl/kg body weight. Doxycycline disposition fitted an open two-compartment model. The mean (+/-SD) elimination half-life was 10.6 +/- 0.7, 10.8 +/- 1.5, 7.9 +/- 1.4 and 10.0 +/- 0.9 h in 3 day, 3-, 6- and 12-week-old turkeys, respectively. Mean (+/- SD) total body clearance was 0.19 (+/-0.01), 0.27 (+/-0.03), 0.11 (+/-0.03) and 0.06 (+/-0.01) L/h.kg in 3 day, 3-, 6- and 12-week-old turkeys, respectively. The steady-state volume of distribution was 1.77 (+/-0.2), 2.1 (+/-0.2), 0.7 (+/-0.4) and 0.5 (+/-0.2) L/kg in turkeys of the above mentioned ages, respectively. The AUC value significantly increased with the age of the turkeys. An oral doxycycline solution at a single dose of 25 mg/kg of body weight was administered to 3 day. 3-, 6- and 12-week-old turkeys. The maximal plasma concentrations in fasted turkeys were 3.8, 5.6, 7.4 and 5.7 micrograms/mL. with tmax values of 4.7, 1.5, 2.8 and 5.4 h, for the different ages, respectively. In fed turkeys the Cmax values were 2.5, 6.1, 4.8 and 3.0 micrograms/mL. with tmax values of 4.2, 5.3, 4.5 and 7.5 h, respectively. The absolute bioavailability in fasted turkeys varied between 25.0 +/- 9.0% (for 12-week-old birds) and 63.5 +/- 7.1% (for 3-week-old birds). The relative bioavailability varied between 40.0 +/- 13.0% (for 12-week-old birds) and 83.7 +/- 14.3% (for 3-week-old birds).

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004318 Doxycycline A synthetic tetracycline derivative with similar antimicrobial activity. 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-,Alpha-6-Deoxyoxytetracycline,Atridox,BMY-28689,BU-3839T,Doryx,Doxycycline Calcium,Doxycycline Calcium Salt (1:2),Doxycycline Hemiethanolate,Doxycycline Hyclate,Doxycycline Monohydrate,Doxycycline Monohydrochloride, 6-epimer,Doxycycline Monohydrochloride, Dihydrate,Doxycycline Phosphate (1:1),Doxycycline-Chinoin,Hydramycin,Oracea,Periostat,Vibra-Tabs,Vibramycin,Vibramycin Novum,Vibravenos,Alpha 6 Deoxyoxytetracycline,BMY 28689,BMY28689,BU 3839T,BU3839T,Doxycycline Chinoin,Doxycycline Monohydrochloride, 6 epimer,Vibra Tabs
D005772 Gastrointestinal Transit Passage of food (sometimes in the form of a test meal) through the gastrointestinal tract as measured in minutes or hours. The rate of passage through the intestine is an indicator of small bowel function. GI Transit,GI Transits,Gastrointestinal Transits,Transit, GI,Transit, Gastrointestinal,Transits, GI,Transits, Gastrointestinal
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000327 Adsorption The adhesion of gases, liquids, or dissolved solids onto a surface. It includes adsorptive phenomena of bacteria and viruses onto surfaces as well. ABSORPTION into the substance may follow but not necessarily. Adsorptions
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging

Related Publications

M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
November 1986, Arzneimittel-Forschung,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
February 2000, Journal of veterinary pharmacology and therapeutics,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
January 2001, Acta veterinaria Hungarica,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
March 1993, The veterinary quarterly,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
December 2006, Journal of veterinary science,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
November 1979, Antibiotiki,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
October 1974, Current therapeutic research, clinical and experimental,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
September 1990, Arzneimittel-Forschung,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
August 1974, Casopis lekaru ceskych,
M D Santos, and H Vermeersch, and J P Remon, and M Schelkens, and P De Backer, and H J Van Bree, and R Ducatelle, and F Haesebrouck
December 2020, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment,
Copied contents to your clipboard!